Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Lmcg Investments LLC

Lmcg Investments LLC boosted its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 231.3% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 14,481 shares of the biopharmaceutical company's stock after purchasing an additional 10,110 shares during the quarter. Lmcg Investments LLC's holdings in Regeneron Pharmaceuticals were worth $9,184,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of the company. Capital International Investors lifted its position in shares of Regeneron Pharmaceuticals by 41.6% in the fourth quarter. Capital International Investors now owns 4,736,929 shares of the biopharmaceutical company's stock valued at $3,373,859,000 after acquiring an additional 1,390,534 shares in the last quarter. Geode Capital Management LLC lifted its position in shares of Regeneron Pharmaceuticals by 6.8% in the fourth quarter. Geode Capital Management LLC now owns 2,427,630 shares of the biopharmaceutical company's stock valued at $1,726,940,000 after acquiring an additional 155,369 shares in the last quarter. Dodge & Cox lifted its position in shares of Regeneron Pharmaceuticals by 0.4% in the fourth quarter. Dodge & Cox now owns 2,321,316 shares of the biopharmaceutical company's stock valued at $1,653,543,000 after acquiring an additional 9,381 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in shares of Regeneron Pharmaceuticals by 63.5% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 2,085,447 shares of the biopharmaceutical company's stock valued at $1,485,527,000 after acquiring an additional 810,144 shares in the last quarter. Finally, Franklin Resources Inc. lifted its position in shares of Regeneron Pharmaceuticals by 7.9% in the fourth quarter. Franklin Resources Inc. now owns 2,045,210 shares of the biopharmaceutical company's stock valued at $1,456,864,000 after acquiring an additional 149,124 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Regeneron Pharmaceuticals Stock Up 2.1%

Shares of REGN stock traded up $10.15 during trading hours on Friday, reaching $493.22. The company had a trading volume of 1,497,861 shares, compared to its average volume of 862,784. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $1,211.20. The company has a market capitalization of $53.25 billion, a P/E ratio of 12.88, a price-to-earnings-growth ratio of 2.34 and a beta of 0.31. The stock's fifty day simple moving average is $569.75 and its 200 day simple moving average is $656.48.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The company had revenue of $3.03 billion during the quarter, compared to analyst estimates of $3.40 billion. During the same quarter last year, the business posted $9.55 EPS. Regeneron Pharmaceuticals's quarterly revenue was down 3.7% compared to the same quarter last year. As a group, sell-side analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, June 6th. Shareholders of record on Tuesday, May 20th were paid a dividend of $0.88 per share. The ex-dividend date was Tuesday, May 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.71%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 8.96%.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Robert W. Baird reduced their price objective on Regeneron Pharmaceuticals from $759.00 to $652.00 and set a "neutral" rating on the stock in a research report on Friday, April 25th. Canaccord Genuity Group upgraded Regeneron Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a research report on Tuesday, April 22nd. Wall Street Zen downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Thursday, May 1st. Royal Bank of Canada downgraded Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 target price on the stock. in a research report on Friday, May 30th. Finally, Bank of America reduced their target price on Regeneron Pharmaceuticals from $575.00 to $547.00 and set an "underperform" rating on the stock in a research report on Thursday, April 17th. One research analyst has rated the stock with a sell rating, six have issued a hold rating, seventeen have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $844.48.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.